Acrongenomics Inc. is pleased to introduce the revolutionary design of its nanobiotechnology product, the Neo-EpCAM(TM) cancer detection kit, which fuses molecular diagnostics with nanotechnology.
The Neo-EpCAMTM kit will be used for the detection of cancers of epithelial origin such as, lung, breast, colon, prostate, head and neck, stomach, ovary, pancreas, oesophagus, and larynx.
The Neo-EpCAM(TM) cancer detection kit can be performed on the most commonly used technological platform, the PCR (Polymerase Chain Reaction), for molecular diagnostics. The never-before-seen rapidity in molecular diagnostics will now have the advantage of increased sensitivity and specificity. The diagnostic test can be performed by personnel already trained and familiar with the PCR, and does not require additional scientific skills.
The technology dramatically reduces lab result time and labour costs by up to 75%, thereby substantially increasing productivity to all diagnostic centers and laboratories. As a result, this significant improvement offers patients better service and benefits.
Progress on Neo-EpCAMTM evaluation studies has brought Acrongenomics one step closer to the development of a commercial product.
Important Information About Forward-Looking Statements
All statements in this news release, that are other than statements of historical facts, are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
Source: Acrongenomics Inc.
Explore further: New nanodevice defeats drug resistance